Mayo Clinic College of Medicine, Rochester, MN, USA.
Clin Gastroenterol Hepatol. 2011 Jan;9(1):64-70. doi: 10.1016/j.cgh.2010.08.019. Epub 2010 Sep 8.
BACKGROUND & AIMS: There are few data available about the prevalence or effects of cirrhosis in patients with hepatocellular carcinoma (HCC) from viral hepatitis. We compared patients with HCC and hepatitis B virus (HBV) or hepatitis C virus (HCV) infections to determine the proportions of cirrhosis in each group, virologic and tumor characteristics, and overall survival.
This analysis included patients with HBV (n = 64) or HCV (n = 118) infection who were diagnosed with HCC at the Mayo Clinic in Rochester, Minnesota from 1994-2008; groups were matched for age and sex. The diagnosis of cirrhosis was based on histology and, if histologic information was insufficient or unavailable, clinical indicators that included ascites or varices, thrombocytopenia or splenomegaly, and radiographic configuration of cirrhosis. Virologic characteristics, tumor stage, and patient survival were also assessed.
The prevalence of histologic cirrhosis was 88% among patients with HBV infection and 93% among those with HCV infection (P = .46). When the most inclusive criteria for cirrhosis were applied, cirrhosis was present in 94% of patients with HBV and 97% with HCV (P = .24). Among HCV patients, 5.2% were negative for HCV RNA after antiviral treatment; 63.4% of HBV patients had HBV DNA <2000 IU/mL with or without treatment. Patients with HBV tended to have less surveillance and more advanced stages of HCC, without differences in survival from those with HCV infection (P = .75).
Most patients with HCC and chronic viral hepatitis had evidence of cirrhosis, including those with HBV infection and those without active viral replication.
关于乙型肝炎病毒(HBV)或丙型肝炎病毒(HCV)感染所致肝细胞癌(HCC)患者肝硬化的患病率或影响,相关数据较少。我们比较了 HCC 合并 HBV 或 HCV 感染患者,以确定每组肝硬化的比例、病毒学和肿瘤特征以及总生存率。
本分析纳入了 1994 年至 2008 年在明尼苏达州罗切斯特市梅奥诊所诊断为 HCC 的 HBV(n = 64)或 HCV(n = 118)感染患者;按年龄和性别匹配。肝硬化的诊断基于组织学,如组织学信息不足或不可用,则依据腹水或静脉曲张、血小板减少或脾肿大以及肝硬化的影像学特征等临床指标进行诊断。还评估了病毒学特征、肿瘤分期和患者生存情况。
HBV 感染患者中组织学肝硬化的患病率为 88%,HCV 感染患者为 93%(P =.46)。当采用最广泛的肝硬化标准时,HBV 患者中 94%存在肝硬化,HCV 患者中 97%存在肝硬化(P =.24)。在 HCV 患者中,抗病毒治疗后有 5.2%的患者 HCV RNA 阴性;有或无治疗,HBV 患者中有 63.4%的 HBV DNA <2000 IU/mL。HBV 患者的监测较少,HCC 分期更晚期,但与 HCV 感染患者的生存无差异(P =.75)。
大多数 HCC 合并慢性病毒性肝炎患者有肝硬化证据,包括 HBV 感染和无活跃病毒复制的患者。